Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGEN

Agenus (AGEN)

Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateTimeSourceHeadlineSymbolCompany
10/06/20234:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
10/05/20237:30AMBusiness WireAgenus To Host BOT/BAL Program Update at ESMO 2023NASDAQ:AGENAgenus Inc
10/04/20235:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
10/04/20235:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
10/04/20235:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
09/01/20234:30PMBusiness WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
08/31/20235:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/28/20235:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/28/20237:30AMBusiness WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
08/23/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
08/23/20238:00AMBusiness WireAgenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple CancersNASDAQ:AGENAgenus Inc
08/09/20238:30AMBusiness WireSaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell AdjuvantNASDAQ:AGENAgenus Inc
08/08/20234:04PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
08/08/20237:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
08/08/20237:30AMBusiness WireAgenus Reports Second Quarter 2023 ResultsNASDAQ:AGENAgenus Inc
07/28/20237:30AMBusiness WireAgenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023NASDAQ:AGENAgenus Inc
07/26/20237:30AMBusiness WireAgenus to Provide Second Quarter 2023 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
07/20/20237:30AMBusiness WireAgenus Expands Executive Leadership TeamNASDAQ:AGENAgenus Inc
07/06/20234:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
07/06/20234:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
07/06/20234:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
06/30/202311:15AMBusiness WireESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal CancerNASDAQ:AGENAgenus Inc
06/23/20235:30PMEdgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:AGENAgenus Inc
06/15/20234:17PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AGENAgenus Inc
06/05/20239:49AMBusiness WireAgenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCONASDAQ:AGENAgenus Inc
06/05/20237:30AMBusiness WireAgenus Announces Virtual Annual Shareholders MeetingNASDAQ:AGENAgenus Inc
05/25/20237:30AMBusiness WireAgenus to Participate in Jefferies Healthcare ConferenceNASDAQ:AGENAgenus Inc
05/09/20238:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AGENAgenus Inc
05/09/20238:00AMBusiness WireAgenus Provides Corporate Update and First Quarter 2023 Financial ResultsNASDAQ:AGENAgenus Inc
05/03/20239:08AMBusiness WireAgenus Selected for Late-Breaking Oral Presentation at ESMO-GINASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN